Immunochemotherapy was effective and well tolerated for the treatment of patients with metastatic renal cell carcinoma, according to the results of a prospective phase II study reported in the Oct. 1 issue of Cancer.
Resection of residual disease is therefore justified. “Patients who achieved complete remission had durable remission and survival,” write Eliahu Gez, MD, from the Rambam Medical Center in Haifa, Israel, and colleagues.
“There was a positive correlation between response to treatment and survival.” Of 62 study subjects with metastatic renal cell carcinoma involving lungs, lymph nodes, bone, kidney, and/or liver, 54 had nephrectomy prior to immunochemotherapy with interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine.
Eastern Cooperative Oncology Group performance status was one in 45 patients and two in 17 patients; median age was 63 years, and median follow-up was 34 months.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!